Radiopharm Theranostics disclosed that its Phase 2b study of the 18F‑RAD 101 small‑molecule imaging agent achieved a 92 % MRI‑concordance rate among the 12 evaluable patients enrolled to date. The 11 of 12 patients whose scans were deemed evaluable showed perfect agreement between RAD 101 PET and standard MRI, confirming the agent’s ability to accurately identify brain metastases from solid tumors such as lung, breast, and melanoma.
The interim data were generated from the first 12 of the 30 patients in the single‑arm U.S. trial. The 92 % concordance rate meets the study’s primary endpoint and aligns with the 90 % concordance observed in the earlier Phase 2a cohort, reinforcing the consistency of the imaging signal across patient populations. The company’s CEO, Riccardo Canevari, said the result “validates our target‑based approach and strengthens the case for a larger, confirmatory study.”
Radiopharm’s 18F‑RAD 101 is designed to bind fatty acid synthase, an enzyme overexpressed in many solid tumors. By highlighting metabolic activity, the agent aims to distinguish true tumor recurrence from radiation necrosis—a major diagnostic challenge for over 300,000 U.S. patients with brain metastases each year. The company estimates the U.S. market for a high‑accuracy brain‑metastasis imaging agent exceeds $500 million annually, positioning RAD 101 as a potentially high‑value product if regulatory approval is obtained.
The company’s financial position supports continued development. As of December 31 2025, Radiopharm reported a cash balance of $34.52 million, providing a runway into 2027. The firm’s recent capital raise of A$35 million in October 2025, combined with existing cash, underpins the planned Phase 3 registration effort and potential partnership or acquisition discussions.
Analysts have maintained a “Buy” consensus on the stock, with a target price of $15.33, reflecting confidence in the company’s pipeline and the strong interim data. The positive reception underscores the market’s view that the 92 % concordance rate and Fast‑Track designation are significant milestones that could accelerate regulatory review and broaden the company’s commercial prospects.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.